Cullinan Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 37.15 million compared to USD 57.96 million a year ago. Basic loss per share from continuing operations was USD 0.86 compared to USD 1.42 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.5 USD | +3.12% | -2.61% | +130.62% |
05-15 | Cullinan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-15 | Cullinan Therapeutics, Inc. Announces Board Changes | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+130.62% | 1.31B | |
+43.36% | 58.06B | |
-5.31% | 40.53B | |
+37.52% | 38.99B | |
+14.75% | 26.7B | |
-12.56% | 26.56B | |
-22.45% | 18.98B | |
+0.04% | 12.17B | |
+25.12% | 12B | |
+26.04% | 11.92B |
- Stock Market
- Equities
- CGEM Stock
- News Cullinan Therapeutics, Inc.
- Cullinan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024